Palatin Technologies' CEO Discusses F2Q2012 Results - Earnings Call Transcript

Palatin Technologies Inc. ( PTN)

F2Q12 Earnings Call

February 15, 2012 11:00 am ET

Executives

Dr. Carl Spana - President & CEO

Steve Wills - CFO & COO

Analysts

Rahul Jasuja - Noble Financial

David Moskowitz - Roth Capital

Adam Selkin - Chardan Capital Markets

Presentation

Operator

Good morning, ladies and gentlemen and welcome to the Palatin Technologies second quarter fiscal year 2012 conference call. As a reminder, this conference call is being recorded.

Before we begin our remarks, I would like to remind you that statements by Palatin that are not historical facts maybe forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate and actual results could differ materially from those anticipated due to a variety of risks and uncertainties discussed in the company’s most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements and Palatin’s prospects.

Now I would like to introduce you to your host for today, Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies. Please go ahead, sir.

Dr. Carl Spana

Thank you. Good morning. I’m Carl Spana, President and CEO of Palatin Technologies. With me on the call today is Steve Wills, our Chief Financial and Operating Officer and Executive Vice President; and Dr. Jeffrey Edelson, our Chief Medical Officer.

On today’s call, we will be providing updates on our product programs and financial results. To begin, Steve Wills will provide an update on our fiscal second quarter 2012 financial results. Steve?

If you liked this article you might like

How to Trade Today's Most Active Stocks -- Ford, Palatin, More

Palatin Female Libido-Boosting Shot Fails Crucial Sex Frequency Test

Insider Trading Alert - AEL, PTN And BSX Traded By Insiders

Palatin Technologies (PTN) Stock Up After FDA Approval of 'Female Viagra'

Palatin Technologies (PTN) Stock Climbing on FDA Approval of 'Female Viagra'